首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Unexpected In Vivo Activity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo-β-Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model
【2h】

Unexpected In Vivo Activity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo-β-Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model

机译:头孢他啶单独和与阿维巴坦联用对小鼠大腿感染模型中新德里金属-β-内酰胺酶生产肠杆菌科细菌的意外体内活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The emergence of the New Delhi metallo-β-lactamase (NDM) among Enterobacteriaceae has become a global concern because of its high levels of in vitro resistance to nearly all available antibiotics. However, recent in vivo studies demonstrated the efficacies of carbapenems against NDM-1-producing isolates despite high MICs. Herein, we report in vivo findings with ceftazidime and ceftazidime-avibactam against an isogenic pair (wild type and NDM-1) and four clinical NDM-producing isolates that demonstrate discordance between MICs measured in vitro and the in vivo activity of ceftazidime-avibactam against this resistant genotype.
机译:肠杆菌科细菌中新德里金属-β-内酰胺酶(NDM)的出现已成为全球关注的问题,因为其对几乎所有可用抗生素的体外耐药性都很高。然而,最近的体内研究证明了碳青霉烯类化合物对MIC的产生具有很高的抵抗NDM-1产生菌的功效。在本文中,我们报告了头孢他啶和头孢他啶-avibactam对同基因对(野生型和NDM-1)和四种临床NDM分离株的体内发现,这些分离物证明了在体外测量的MIC与头孢他啶-avibactam的体内活性之间存在差异这种抗性基因型。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号